Term
|
Definition
CH 54 Cancer Chemotherapy
Alkylating Agents
Transfer alkyl groups to various cellular constituents. Alkylations of DNA within the nucleus probably represent the major interactions that lead to cell death.
|
Occur in rapidly growing tissues – bone marrow, GI tract, reproductive system
Nausea and vomiting
|
Cancer
|
|
|
|
Term
|
Definition
CH 54 Cancer Chemotherapy
Alkylating Agents
Transfer alkyl groups to various cellular constituents.Alkylations of DNA within the nucleus probably represent the major interactions that lead to cell death.
|
Occur in rapidly growing tissues – bone marrow, GI tract, reproductive system
Nausea and vomiting
|
Cancer
|
|
|
|
Term
|
Definition
CH 54 Cancer Chemotherapy
Alkylating Agents
Transfer alkyl groups to various cellular constituents.Alkylations of DNA within the nucleus probably represent the major interactions that lead to cell death.
|
Occur in rapidly growing tissues – bone marrow, GI tract, reproductive system
Nausea and vomiting
|
Cancer
|
|
|
|
Term
|
Definition
CH 54 Cancer Chemotherapy
Antimetabolites
Folate analog that inhibits dihdrofolate reductase (DHFR), interfering with the synthesis of tetrahydrofolate (THF), which is a key one-carbon carrier for purine nucleotide synthesis.
|
Mucositis, myelosuppression with neutropenia and thrombocytopenia
Hepatic toxicity
|
Breast cancer, head and neck cancer, osteogenic sarcoma, primary central nervous system lymphoma, non-Hodgkin’s lymphoma, bladder cancer, choriocarcinoma
|
|
|
|
Term
|
Definition
CH 54 Cancer Chemotherapy
Antimetabolites
Inhibits purine nucleotide synthesis; incorporates triphosphate into RNA and DNA
|
Myelosuppression, immunosuppression, hepatotoxicity
|
Acute myelogenous leukemia (AML)
|
|
|
|
Term
|
Definition
CH 54 Cancer Chemotherapy
Antimetabolites
Inhibits thymidine synthase; incorporates 5-fluorouridine-5’-triphosphate (FUTP) into RNA resulting in alteration in RNA processing; incorporation of FdUTP into DNA resulting in inhibition of DNA synthesis
|
Mucositis, bone marrow depression, neurotoxicity
|
Colorectal cancer, anal cancer, breast cancer, gastroesophageal cancer, head and neck cancer hepatocellular cancer
|
|
|
|
Term
|
Definition
CH 54 Cancer Chemotherapy
Mitotic Spindle Inhibitors
Inhibition of tubulin polyermization, which disrupts assembly of microtubules. This results in mitotic arrest in metaphase leading to cell death.
|
Myelosuppression, mucositis, alopecia, SIADH, vascular events
|
Hodgkin’s and non-Hodgkins’ lymphoma, germ cell cancer, breast cancer, Kaposi’s sarcoma
|
|
|
|
Term
|
Definition
CH 54 Cancer Chemotherapy
Mitotic Spindle Inhibitors
Inhibition of tubulin polyermization, which disrupts assembly of microtubules. This results in mitotic arrest in metaphase leading to cell death.
|
Neurotoxicity with peripheral neuropathy, paralytic ileus, myelosuppression, alopecia, SIADH
|
Acute lymphoblastic anemia (ALL), Hodgkin’s and non-Hodgkin’s lymphoma, rhabdomyosarcoma, neuroblastoma, Wilms’ tumor
|
|
|
|
Term
|
Definition
CH 54 Cancer Chemotherapy
Mitotic Spindle Inhibitors
Acts as mitotic spindle poison by binding to microtubules and enhancing tubulin polymerization in the absence of microtubule-associated proteins and guanosine triphosphate. Results in inhibition of mitosis and cell division.
|
Hypotension, arrhythmias, hypersensitivity, myelosuppression, peripheral sensory neuropathy
|
Breast, non-small cell and small cell lung, ovarian, prostate gastroesophageal, bladder, head and neck
|
|
|
|
Term
|
Definition
CH 54 Cancer Chemotherapy
Topoisomerase Inhibitors
Inhibits topoisomerase II, which results in
DNA damage through strand breakage induced by the formation of a ternary complex of drug, DNA, and enzyme
|
Hypotension, alopecia, myelosuppression
|
Non-small and small cell lung, non-Hodgkin’s lymphoma, gastric
|
|
|
|
Term
|
Definition
CH 54 Cancer Chemotherapy
Topoisomerase Inhibitors
Inhibit topoisomerase I, the key enzyme for cutting and re-ligating single DNA strands, resulting in DNA damage.
|
myelosuppression
|
Small cell lung, ovarian
|
|
|
|
Term
|
Definition
CH 54 Cancer Chemotherapy
Antibiotics
Cytotoxic action through 4 mechanisms:
(1) Inhibits topoisomerase II
(2) Binds to DNA through intercalation, which blocks synthesis of DNA and RNA, and causes DNA strand scission
(3) Generation of free radicals
(4) Bind to cellular membranes to alter fluidity and ion transport
|
Red urine (not hematuria), alopecia, myelosuppression, stomatitis
Cardiac toxicity: (acute) arrhythmias, pericarditis, myocarditis; (chronic) cardiomyopathy and heart failure
|
Breast, Hodgkin’s and non-Hodgkin’s lymphoma, soft tissue sarcoma, ovarian, non-small and small cell lung, thyroid, Wilms’ tumor, neuroblastoma
|
|
|
|
Term
|
Definition
CH 54 Cancer Chemotherapy
Antibiotics
Oxygen free radicals bind to DNA causing single- and double-strand DNA breaks
|
Allergic reactions, fever, hypotension, skin toxicity, pulmonary fibrosis, mucositis, alopecia
|
Hodgkin’s and non-Hodgkin’s lymphoma, germ cell, head and neck
|
|
|
|
Term
|
Definition
CH 54 Cancer Chemotherapy
Antibiotics
Acts as an alkylating agent and forms cross-links with DNA; formation of oxygen free radicals, which target DNA
|
Myelosuppression, mucositis, anorexia and fatigue, hemolytic-uremic syndrome
|
Superficial bladder, gastric, breast, non-small cell lung, head and neck
|
|
|
|
Term
|
Definition
CH 54 Cancer Chemotherapy
Hormonal Agents
Androgen receptor antagonist
|
Mild gynecomastia, reversible hepatic toxicity
|
Prostate cancer
|
|
|
|
Term
|
Definition
CH 54 Cancer Chemotherapy
Hormonal Agents
Selective estrogen receptor modulator (SERM); competitive partial agonist inhibitor of estradiol at the estrogen receptor
Estrogen receptor antagonist (breasts)
Estrogen receptor agonist (bones)
|
Hot flushes, nausea, vomiting
|
Palliative treatment of breast cancer in postmenopausal women and chemoprevention of breast cancer in high-risk women;
prevent osteoporosis
|
|
|
|
Term
|
Definition
CH 54 Cancer Chemotherapy
Hormonal Agents
Glucocorticoid
|
Hypertension, fluid retention, diabetes, ↑susceptibility infection
Cataracts, fat redistribution, glaucoma, muscle wasting, peptic ulcers
|
Rx: control proliferation of
corticosteroid sensitive tumors
(Hodgkin's, non-Hodgkin's, etc.)
|
|
|
|
Term
|
Definition
CH 54 Cancer Chemotherapy
Hormonal Agents
GnRH receptor agonist; suppresses FSH &
LH release in the long-term
|
Gynecomastia, hot flashes,
impotence
|
prostate
|
|
|
|
Term
|
Definition
CH 54 Cancer Chemotherapy
Hormonal Agents
Selective nonsteroidal inhibitor of aromatase, the enzyme required for estrogen synthesis
|
Fatigue, hot flashes, arthralgias
|
Breast cancer
|
|
|
|